Navigation Links
Jury Returns Verdict in VNUS' Patent Infringement Lawsuit With Total Vein Systems and biolitec Finding Some Patent Claims Invalid and Some Infringed
Date:12/9/2010

HOUSTON, Dec. 9, 2010 /PRNewswire/ -- After a lengthy seven-week trial in VNUS' lawsuit against Total Vein Solutions, LLC d/b/a Total Vein Systems ("TVS") and biolitec, Inc. ("biolitec"), a federal jury in San Francisco has returned a verdict finding invalidity of many of the claims of VNUS' patents, and infringement of others.  

"TVS agrees with the jury's findings that certain claims in VNUS' '084, '803 and '355 patents were invalid as "obvious," but is displeased with the jury's verdict of infringement and damages."  Tyri Schiek, President and co-owner of TVS commented, "It has always been and remains our position that TVS does not infringe anyone's patents by selling unpatented, standard medical supplies.  We believe all of the VNUS method patents are invalid."   David Centanni, co-owner and CEO of TVS, added that "we disagree with the jury's conclusion on infringement and think the jury's findings on damages were grossly inflated.  TVS will continue business as usual and is confident that those findings of the jury that were in error will be overturned, either by the trial court or at the appellate level.  Total Vein remains dedicated to providing the highest quality medical products to physicians and clinics at fair and equitable prices."

VNUS sued TVS, among others, in 2008, for indirect patent infringement, by way of contributory and induced infringement, relating to TVS' sales of laser fibers, laser consoles, introducer kits and procedure packs.  The patents at issue do not cover a particular product or device, but instead claim a method of performing endovenous ablation with vein compression.  

TVS has steadfastly denied that its sales of unpatented products amount to infringing conduct.  TVS also noted that the patents do not adequately enable doctors to perform the methods using laser or microwave energy modalities without "undue experimentation," despite claiming such.  Moreover, TVS and biolitec argued that a variety of publications show that the same endovenous ablation methods existed long before, and that VNUS' claimed procedure is merely an obvious variant of such earlier described methods.  

TVS expects that it will file all necessary motions in the trial court to overturn the portions of the jury's decision that were in error, and will appeal where necessary.  Contact: David Centanni, CEO and co-ownerTyri Schiek, President and co-owner888 868-8346
'/>"/>

SOURCE Total Vein Solutions, LLC d/b/a Total Vein Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Blood Donors Needed as School, Fall Season Returns
2. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
3. Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
4. Molecular Devices Returns to Life Sciences Marketplace
5. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
6. Segal McCambridge Singer & Mahoney, Ltd. and Greenberg Traurig, LLP Obtain Three Defense Verdicts for I-Flow in Oregon Infusion Pump Cases
7. Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
8. Maryland Woman Thankful for Wyeth Verdicts
9. Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment
10. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
11. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
Breaking Medicine News(10 mins):